EICHORCondition: Degenerative Disc Disease · Disc Degeneration · Lumbar Discogenic Pain · Sponsor: VIVEX Biologics, Inc.
VIA Disc NP is an off-the-shelf minimally processed human nucleus pulposus tissue allograft intended to supplement degenerated intervertebral discs. The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (\> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels. Participants who consent to participate in the study and meet all eligibility criteria during the Screening/Baseline period will return on Day 1 to be randomized to either the VIA Disc NP or sham-control group. At 12-weeks post-treatment, participants allocated to the sham-control group will be given the option to crossover to the VIA Disc NP group if they meet the requirement to crossover. All participants will be followed through 52-weeks post-treatment at which time they will be asked if they would like to consent to participate in an extended long-term follow-up period. The sham-control group participants who did not crossover at 12-weeks will be exited from the study at this visit. If participants consent to participate in the extended long-term follow-up period, the VIA Disc NP group will be followed through 24-Months and the sham-control group will be followed through 27-months. If the participant declines participation, they will be ex…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Key Inclusion Criteria: 1. Age 22 to 85 years old 2. Diagnosis of early to moderate DDD, Modified Pfirrmann Grade 3-7 3. Chronic axial midline low-back pain with or without referred non-radicular leg pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care 4. Positive hip flexion test as confirmed with the Neurologic Exam indicating positive provocation with sustained hip flexion at the time of screening 5. Demonstrated intolerance to sitting for more than 30 minutes at a time based on self-report or assessed by a qualified healthcare professional at the screening visit 6. Low-back pain severity score of ≥ 40 to ≤ 90 mm on the VAS at the time of Screening 7. ODI score of ≥ 40 to ≤ 80 at the time of Screening Key Exclusion Criteria: 1. Contraindication to MRI for any reason 2. Contraindications to the proposed sedation/anesthetic protocol 3. Symptomatic involvement of more than two lumbar discs 4. Fracture of the lumbar spine, previous lumbar spine surgery or previous treatment of the target disc(s) 5. Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes around the target disc 6. Clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology 7. Clinical suspicion of facet pain as primary pain generator 8. Women who are pregnant or breastfeeding at the time of enrollment and/or plan to become pregnant during the study. Pregnancy is confirmed by: * A positive pregnancy test during the screening visit * Self-reported pregnancy 9. Women of childbearing potential (WOCBP) who are not using a reliable form of contraception (as determined by the Investigator)
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Genesis Research Services Pty Ltd | Broadmeadow, New South Wales, Australia | — |
| Australian Medical Research | Hurstville, New South Wales, Australia | — |
| Sydney Pain Research Centre | Wahroonga, New South Wales, Australia | — |
| Cercare Clinical Research | Wayville, South Australia, Australia | — |
| Monash House Research Centre Pty Ltd | Clayton, Victoria, Australia | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06615505